Fig. 4. MDSCs are capable of inducing PD-1⁻PD-L1 B cells in vivo⁺.

Normal mice were intravenously injected with congenic tumor-derived MDSCs (3 × 10⁷) every 2 days (n = 5). Normal mice were injected with PBS and used as the control group. After 1 week, the proportions of MDSCs (a) and PD-1⁻PD-L1⁺ B cells (b) in the spleen, peripheral blood, and bone marrow were measured by FC. (In all experiments, Bar graphs and plots represent or include mean ± SD, respectively. ns no statistically significant, ***p < 0.001).